Astrazeneca Pharma India Ltd.
Snapshot View

3267.05 -60.60 ▼-1.8%

02 December 2022, 04:01:00 PM
Volume: 912

Overview View Details >>

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.astrazenecaindia.com/india
Market Cap 8,189.13 Cr.
Enterprise Value(EV) 7,697.89 Cr. 2022-09
Financial Indicators
Earnings per share (EPS) 36.85 Trailing Twelve Months Ending 2022-09
Price-Earning Ratio (PE) 88.89 Trailing Twelve Months Ending 2022-09
Industry PE 35.40 Trailing Twelve Months Ending 2022-09
Book Value / Share 217.47 Trailing Twelve Months Ending 2022-09
Price to Book Value 15.06 Calculated using Price: 3,275.65
Dividend Yield 0.31 Period Ending 2022-03
No. of Shares Subscribed 2.50 Cr. 25,000,000 Shares
FaceValue 2
Company Profile
The Company is engaged in the business of manufacture, distribution and marketing of life-changing medicines in crucial areas of healthcare including oncology, cardiovascular, diabetes, renal, metabolic and respiratory. The company has an innovative portfolio in crucial areas of healthcare including cardiovascular, renal & metabolic diseases, oncology and respiratory. AstraZeneca Pharma India is a subsidiary of AstraZeneca Pharmaceuticals AB, Sweden, which is an indirect subsidiary of AstraZeneca PLC.

Delivery View Details >>

Delivered Qty
Traded Qty

Performance View Details >>

1 Day
-1.82%
1 Week
-2.69%
1 Month
-4.04%
3 Month
+7.73%
6 Month
+11.44%
1 Year
+5.22%
2 Year
-27.43%
5 Year
+194.43%
10 Year
+113.95%
9 years 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03 2022-03
Return on Equity (%) -0.38 -12.93 3.43 10.63 11.12 20.03 21.83 22.83 12.78
Return on Capital Employed (%) -12.93 3.76 18.74 18.65 26.53 34.61 31.24 17.36
Return on Assets (%) -0.14 -5.04 1.25 4.25 4.76 9.34 10.57 11.31 6.65

Balance Sheet View Details >>

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2022-09* Rs. Cr.
Shh. Funds 172 151 156 223 247 301 364 456 511 544
Non Curr. Liab. 0 1 39 89 110 23 44 45 74 -7
Curr. Liab. 244 260 234 202 219 268 367 373 392 342
Minority Int.
Equity & Liab. 416 412 429 514 575 591 776 874 977 879
Non Curr. Assets 141 148 162 250 243 178 193 186 212 130
Curr. Assets 275 263 267 263 333 413 582 689 765 748
Misc. Exp. not W/O
Total Assets 416 412 429 514 575 591 776 874 977 879

Profit Loss View Details >>

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2022-09 Rs. Cr. TTM
Net Sales 474 517 564 544 571 728 832 814 806 901
Other Income 9 6 7 14 12 16 13 13 15 20
Total Income 483 523 571 558 583 745 845 826 820 921
Total Expenditure -487 -528 -547 -507 -525 -657 -711 -678 -719 -780
PBIDT -4 -6 23 51 59 88 134 148 101 141
Interest -1 -1 -1 -1
Depreciation -10 -15 -17 -16 -15 -15 -19 -20 -17 -16
Taxation -1 -1 -15 -18 -18 -42 -34 -21 -33
Exceptional Items 14
PAT -1 -21 5 20 26 54 72 93 62 92
Adjusted EPS 0 -8 2 8 10 22 29 37 25 37

Cash Flow View Details >>

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr.
Cash Fr. Operatn. -6 -1 -46 57 38 9 55 87 105 101
Cash Fr. Inv. -16 -15 -19 -4 0 -9 4 -171 173 5
Cash Fr. Finan. -10 86 -1 -6 -9 -9
Net Change -32 71 -64 53 38 -1 59 -90 269 96
Cash & Cash Eqvt 17 88 23 76 115 114 173 84 352 448

Shareholding Pattern View Details >>

9 Qtrs 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%) 2022-06 (%) 2022-09 (%)
Promoter 75.00 75.00 75.00 75.00 75.00 75.00 75.00 75.00 75.00
Public 25.00 25.00 25.00 25.00 25.00 25.00 25.00 25.00 25.00
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details >>

Fri, 25 Nov 2022
Disclosure Of Related Party Transactions
Pursuant to the provisions of Regulation 23 (9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 as amended we enclose herewith the disclosure of Related Party Transactions for half year ended September 30 2022 for your information and records.
Fri, 25 Nov 2022
Astrazeneca Pharma India Limited Has Received An Import And Market Permission In Form CT-20 (Subsequent New Drug Approval) From The Central Drugs Standard Control Organisation Directorate General Of Health Services Government Of India For Dapagliflozin (Forxiga®) Tablets Of 10 Mg - Additional/ Extended Indication
Please find the enclosed letter of the Company in relation to the captioned subject for your reference.
Fri, 18 Nov 2022
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) and other applicable regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we would like to inform you that the Registrar and Transfer Agents of the Company Integrated Registry Management Services Private Limited have informed the Company on the attached request for Loss of Share Certificate from the claimant

Technical Scans View Details >>

Fri, 02 Dec 2022
Opening at High Opening at High
Closing Below Previous Low Closing Below Previous Low
Close Within 52 Week High Zone Close Within 52 Week High Zone
High Increase 5 Years High Increase 5 Years
CCI Crossed Below -100 CCI Crossed Below -100

Related Stocks View Details >>

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 249,530.84 1,040.00 -0.6%
Cipla Ltd. 89,936.23 1,114.35 -0.9%
Divi's Laboratories Ltd. 89,761.56 3,381.25 -0.8%
Dr. Reddy's Laboratories Ltd. 75,098.21 4,510.40 +0.8%
Apollo Hospitals Enterprise Ltd. 70,043.98 4,871.45 +2.0%
Torrent Pharmaceuticals Ltd. 54,931.39 1,623.05 -1.2%
Max Healthcare Institute Ltd. 43,491.25 448.10 -0.9%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-09 60.50 1,040.00 -0.6%
Cipla Ltd. Consolidated 2022-09 35.23 1,114.35 -0.9%
Divi's Laboratories Ltd. Consolidated 2022-09 29.99 3,381.25 -0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-09 24.23 4,510.40 +0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-09 83.18 4,871.45 +2.0%
Torrent Pharmaceuticals Ltd. Consolidated 2022-09 68.92 1,623.05 -1.2%
Max Healthcare Institute Ltd. Consolidated 2022-09 46.09 448.10 -0.9%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-09 4.68 1,040.00 -0.6%
Cipla Ltd. Consolidated 2022-09 4.13 1,114.35 -0.9%
Divi's Laboratories Ltd. Consolidated 2022-09 7.40 3,381.25 -0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-09 3.63 4,510.40 +0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-09 11.67 4,871.45 +2.0%
Torrent Pharmaceuticals Ltd. Consolidated 2022-09 9.02 1,623.05 -1.2%
Max Healthcare Institute Ltd. Consolidated 2022-09 6.29 448.10 -0.9%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 0.02 1,040.00 -0.6%
Cipla Ltd. Consolidated 2022-03 0.04 1,114.35 -0.9%
Divi's Laboratories Ltd. Consolidated 2022-03 0.00 3,381.25 -0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 0.18 4,510.40 +0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 0.47 4,871.45 +2.0%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 0.68 1,623.05 -1.2%
Max Healthcare Institute Ltd. Consolidated 2022-03 0.12 448.10 -0.9%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 1,040.00 -0.6%
Cipla Ltd. Consolidated 2022-03 13.10 1,114.35 -0.9%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 3,381.25 -0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.55 4,510.40 +0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,871.45 +2.0%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,623.05 -1.2%
Max Healthcare Institute Ltd. Consolidated 2022-03 10.19 448.10 -0.9%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 1,040.00 -0.6%
Cipla Ltd. Consolidated 2022-03 13.10 1,114.35 -0.9%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 3,381.25 -0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.55 4,510.40 +0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,871.45 +2.0%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,623.05 -1.2%
Max Healthcare Institute Ltd. Consolidated 2022-03 10.19 448.10 -0.9%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 38,654.49 1,040.00 -0.6%
Cipla Ltd. Consolidated 2022-03 21,763.34 1,114.35 -0.9%
Divi's Laboratories Ltd. Consolidated 2022-03 8,959.83 3,381.25 -0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 21,545.20 4,510.40 +0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 14,662.60 4,871.45 +2.0%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 8,508.04 1,623.05 -1.2%
Max Healthcare Institute Ltd. Consolidated 2022-03 3,931.46 448.10 -0.9%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 3,405.82 1,040.00 -0.6%
Cipla Ltd. Consolidated 2022-03 2,559.47 1,114.35 -0.9%
Divi's Laboratories Ltd. Consolidated 2022-03 2,960.45 3,381.25 -0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 2,112.20 4,510.40 +0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 1,101.10 4,871.45 +2.0%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 777.18 1,623.05 -1.2%
Max Healthcare Institute Ltd. Consolidated 2022-03 605.05 448.10 -0.9%

FAQ's On Astrazeneca Pharma India Ltd.

What is Astrazeneca Pharma I share price?

Can I buy Astrazeneca Pharma I shares now?

What is the Dividend Yield of Astrazeneca Pharma I?

What is the Market Cap of Astrazeneca Pharma I?

What are the key metrics to analyse Astrazeneca Pharma I?

What is the 52 Week High and Low of Astrazeneca Pharma I?

What is the trend of Astrazeneca Pharma I share price?